Original Study| Volume 15, ISSUE 6, P724-732, December 2017

Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma



      Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and can affect the optimal absorption of concomitant oral medications, such as vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). The purpose of this study was to investigate the effect of PPI use on survival in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.

      Materials and Methods

      We conducted a pooled analysis of mRCC patients treated in phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan–Meier method.


      We identified 2188 patients treated with sunitinib (n = 952), axitinib (n = 626) or sorafenib (n = 610), of whom 120 were PPI users. Overall, PPI users showed similar overall survival compared with non-PPI users (hazard ratio [HR], 1.051; 95% confidence interval [CI], 0.769-1.438; P = .754; median, 24.1 vs. 21.3 months). Similarly, progression-free survival (HR, 1.016; 95% CI, 0.793-1.301; P = .902; median, 5.5 vs. 8.0 months) and objective response rates (23.3% vs. 27.4%; P = .344) were not different between PPI users and nonusers. These findings were consistent across International mRCC Database Consortium risk groups and according to line of therapy. Adverse events were similar between PPI users and nonusers.


      We showed that PPI use does not appear to negatively affect the efficacy and safety of select VEGF-TKIs in patients with mRCC. Documentation of concomitant medications and patient education on potential drug interactions are critical for optimizing the use of oral cancer-targeting therapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rotman S.R.
        • Bishop T.F.
        Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009.
        PLoS One. 2013; 8: e56060
        • Wolf M.
        • Sachs G.
        Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.
        Gastroenterology. 2000; 118: S9
        • Wolf M.
        • Soll A.
        The physiology of gastric acid secretion.
        N Engl J Med. 1988; 319: 1707-1715
        • Shin J.M.
        • Sachs G.
        Pharmacology of proton pump inhibitors.
        Curr Gastroenterol Rep. 2008; 10: 528-534
        • Yin O.Q.
        • Gallagher N.
        • Schran H.
        • et al.
        Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.
        J Clin Pharmacol. 2010; 50: 960-967
        • Lexicomp
        Lexcomp Online: Interactions.
        (Available at:) (Accessed: July 6, 2016)
        • Budha N.R.
        • Frymoyer A.
        • Smelick G.S.
        • et al.
        Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?.
        Clin Pharmacol Ther. 2012; 92: 203-213
        • Di Gion P.
        • Kanefendt F.
        • Jaehde U.
        • et al.
        Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
        Clin Pharmacokinet. 2011; 50: 551-603
        • UpToDate
        Sunitinib: drug information.
        (Available at:) (Accessed: July 6, 2016)
        • UpToDate
        Pazopanib: drug information.
        (Available at:) (Accessed: July 6, 2016)
        • UpToDate
        Sorafenib: drug information.
        (Available at:) (Accessed: July 6, 2016)
        • UpToDate
        Axitinib: drug information.
        (Available at:) (Accessed: July 6, 2016)
        • Tan A.
        • Gibbon D.
        • Stephenson J.
        • et al.
        Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumours.
        Cancer Chemother Pharmacol. 2013; 71: 1635-1643
        • Ha V.H.
        • Ngo M.
        • Chu M.P.
        • et al.
        Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?.
        J Oncol Pharm Pract. 2015; 21: 194-200
        • Barrios C.H.
        • Hernandez-Barajas D.
        • Brown M.P.
        • et al.
        Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
        Cancer. 2012; 118: 1252-1259
        • Escudier B.
        • Roigas J.
        • Gillessen S.
        • et al.
        Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 4068-4075
        • Hutson T.E.
        • Escudier B.
        • Esteban E.
        • et al.
        Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2014; 32: 760-767
        • Hutson T.E.
        • Lesovoy V.
        • Al-Shukri S.
        • et al.
        Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
        Lancet Oncol. 2013; 14: 1287-1294
        • Motzer R.J.
        • Hutson T.E.
        • Olsen M.R.
        • et al.
        Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
        J Clin Oncol. 2012; 30: 1371-1377
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Motzer R.J.
        • Michaelson M.D.
        • Redman B.G.
        • et al.
        Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2006; 24: 16-24
        • Motzer R.J.
        • Rini B.I.
        • Bukowski R.M.
        • et al.
        Sunitinib in patients with metastatic renal cell carcinoma.
        JAMA. 2006; 295: 2516-2524
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931-1939
        • Rini B.I.
        • Melichar B.
        • Ueda T.
        • et al.
        Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
        Lancet Oncol. 2013; 14: 1233-1242
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
      1. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: kidney cancer, version 2.2017.
        (Available at:) (Accessed: January 3, 2017)
        • LeBlanc T.W.
        • McNeil M.J.
        • Kamal A.H.
        • Currow D.C.
        • Abernethy A.P.
        Polypharmacy in patients with advanced cancer and the role of medication discontinuation.
        Lancet Oncol. 2015; 16: e333-e341
        • Chan A.
        • Tan S.H.
        • Wong C.M.
        • Yap K.Y.
        • Ko Y.
        Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists.
        Clin Ther. 2009; 31: 2379-2386
        • Ko Y.
        • Tan S.L.
        • Chan A.
        • et al.
        Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
        Clin Ther. 2012; 34: 1696-1704
        • Popa M.A.
        • Wallace K.J.
        • Brunello A.
        • Extermann M.
        • Balducci L.
        Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.
        J Geriatr Oncol. 2014; 5: 307-314
        • Van Leeuwen R.W.
        • Swart E.L.
        • Boom F.A.
        • Schuitenmaker M.S.
        • Hugtenburg J.G.
        Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method.
        BMC Cancer. 2010; 10: 679
        • Maggiore R.J.
        • Gross C.P.
        • Hurria A.
        Polypharmacy in older adults with cancer.
        Oncologist. 2010; 15: 507-522
      2. Votrient (pazopanib) [prescribing information]. GlaxoSmithKline, Research Triangle Park, NC2014
      3. Post-marketing Experience.
        (Available at:) (Accessed: January 3, 2017)
      4. NEXAVAR (sorafenib) tablets [highlights of prescribing information].
        (Available at:) (Accessed: January 3, 2017)
      5. INLYTA (axitinib) tablets for oral administration.
        (Available at:) (Accessed: January 3, 2017)
        • Au T.H.
        • Bailey E.B.
        • Patel S.B.
        • Tantravahi S.K.
        • Agarwal N.
        • Stenehjem D.D.
        Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC).
        J Clin Oncol. 2016; 34 (abstract 608)
      6. US Food and Drug Administration. Sunitinib (Sutent) prescribing information (2010), Available at: Accessed: January 3, 2017.

      7. US Food and Drug Administration. Axitinib (Inlyta). Clinical Pharmacology and Biopharmaceutics Review (2012). Available at:, Accessed: January 3, 2017.

      8. European Medicines Agency. Sorafenib: EPAR Scientific Discussion (2010), Available at: Accessed: January 3, 2017.

      9. US Food and Drug Administration. Sorafenib (Nexavar): Clinical Pharmacology and Biopharmaceutics Review (2005). Available at: Accessed: January 3, 2017.

        • Lind J.S.
        • Dingemans A.M.
        • Groen H.J.
        • et al.
        A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
        Clin Cancer Res. 2010; 16: 3078-3087
        • Feldman M.
        • Burton M.E.
        Histamine2-receptor antagonists: standard therapy for acid-peptic diseases. 1.
        N Engl J Med. 1990; 323: 1672-1680
        • Van Leeuwen R.W.
        • Van Gelder T.
        • Mathijssen R.H.
        • et al.
        Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
        Lancet Oncol. 2014; 15: e315-e326